PMID- 30431590
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20210110
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 46
DP  - 2018 Nov
TI  - Meta-analysis of clinical trials comparing the efficacy and safety of liposomal 
      cisplatin versus conventional nonliposomal cisplatin in nonsmall cell lung cancer 
      (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN).
PG  - e13169
LID - 10.1097/MD.0000000000013169 [doi]
LID - e13169
AB  - BACKGROUND: While liposomal cisplatin has shown enhanced drug tolerability and 
      higher targeting property as compared with the conventional cisplatin, the doubt 
      remains whether lipoplatin could improve its anticancer efficacy. What's more, 
      there is still no systematic evaluation of the safety profiles of lipoplatin 
      comparing with original cisplatin. Thus, we performed a systematic literature 
      search for randomized clinical trials directly comparing efficacy and safety of 
      liposomal cisplatin versus its conventional nonliposomal cisplatin. METHODS: The 
      electronic search was conducted in PubMed, Embase, The Cochrane Library, and 
      ClinicalTrials.gov from inception to February 10, 2018. The pooled odds ratio 
      (OR) and 95% confidence intervals (CIs) of progressive disease (PD), partial 
      response (PR), stable disease (SD), and adverse events (AEs) were obtained to 
      assess the efficacy and safety. Heterogeneity was estimated using the I test 
      (I > 50%, significant heterogeneity). RESULTS: The search yielded 5 clinical 
      trials that meet inclusion criteria, with a total of 523 patients. We found that 
      the liposome encapsulated cisplatin was more clinical efficacious than cisplatin 
      as assessed by PD rate (OR, 0.46; 95% CI, 0.28-0.74; P = .002), while subgroup 
      analysis of the only nonsmall cell lung cancer (NSCLC) patients showed higher 
      response rates in PR (OR, 0.46; 95% CI, 0.28-0.74; P = .002) and PD (OR, 0.46; 
      95% CI, 0.28-0.74; P = .002) simultaneously. In addition, the toxicity 
      meta-analysis revealed lipoplatin was much less toxic than the original 
      cisplatin, with respect to grade 3 to 4 neurotoxicity (OR, 0.18; 95% CI, 
      0.04-0.74; P = .02), grade 3 to 4 leukopenia (OR, 0.47; 95% CI, 0.26-0.85; 
      P = .01), grade 3 to 4 neutropenia (OR, 0.26; 95% CI, 0.09-0.71; P = .009), grade 
      1 and 2 nausea/vomiting (OR, 0.50; 95% CI, 0.32-0.77; P = .002), and grade 3 and 
      4 asthenia (OR, 0.11; 95% CI, 0.03-0.42; P = .001). CONCLUSIONS: This 
      meta-analysis revealed that with both NSCLC and squamous cell carcinoma of the 
      head and neck (SCCHN) patients, liposomal cisplatin-based chemotherapy offers 
      significant advantages regarding the PD and reduced toxicities relative to 
      conventional cisplatin.
FAU - Xu, Bei
AU  - Xu B
AD  - Department of Clinical Laboratory, Mianyang Central Hospital, Mianyang.
FAU - Zeng, Min
AU  - Zeng M
AD  - Department of Pharmacy, Evidence-Based Pharmacy Center, West China Second 
      University Hospital, Sichuan University, Chengdu, Sichuan, China.
FAU - Zeng, Jiawei
AU  - Zeng J
AD  - Department of Clinical Laboratory, Mianyang Central Hospital, Mianyang.
FAU - Feng, Jiafu
AU  - Feng J
AD  - Department of Clinical Laboratory, Mianyang Central Hospital, Mianyang.
FAU - Yu, Lin
AU  - Yu L
AD  - Department of Clinical Laboratory, Mianyang Central Hospital, Mianyang.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antineoplastic Agents)
RN  - 0 (lipoplatin)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy
MH  - Cisplatin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Lung Neoplasms/*drug therapy
MH  - Squamous Cell Carcinoma of Head and Neck/*drug therapy
MH  - Treatment Outcome
PMC - PMC6257614
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2018/11/16 06:00
MHDA- 2018/12/12 06:00
PMCR- 2018/11/16
CRDT- 2018/11/16 06:00
PHST- 2018/11/16 06:00 [entrez]
PHST- 2018/11/16 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
PHST- 2018/11/16 00:00 [pmc-release]
AID - 00005792-201811160-00032 [pii]
AID - MD-D-18-03808 [pii]
AID - 10.1097/MD.0000000000013169 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Nov;97(46):e13169. doi: 10.1097/MD.0000000000013169.